Pharmaceutical

ASCO 2024: MediLink’s NSCLC and breast cancer ADC shows early safety success

The clinical-stage biotech will share preliminary safety and efficacy data with its ADC at the 2024 ASCO meeting.

May 25, 2024 - 04:00
ASCO 2024: MediLink’s NSCLC and breast cancer ADC shows early safety success
The clinical-stage biotech will share preliminary safety and efficacy data with its ADC at the 2024 ASCO meeting.
Read the original article

Tags:

Previous Article

First made-in-Singapore antibody-drug conjugate EBC-129 progresses to phase 1B d...

Next Article

ASCO 2024: MSD’s ADC shows efficacy in lung and breast tumours

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Biden calls for election wake-up call on abortion rights — but new upheavals are fast approaching

Biden calls for election wake-up call on abortion right...

Mar 8, 2024

STAT+: Medicare holds firm on Alzheimer’s drug coverage policy

STAT+: Medicare holds firm on Alzheimer’s drug coverage...

Jun 4, 2023

Bristol Myers Squibb acquires Karuna Therapeutics for $14bn

Bristol Myers Squibb acquires Karuna Therapeutics for $...

Mar 20, 2024